Mark Kozloff to Vascular Endothelial Growth Factor Receptor-2
This is a "connection" page, showing publications Mark Kozloff has written about Vascular Endothelial Growth Factor Receptor-2.
Connection Strength
0.020
-
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
Score: 0.020
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.